Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A Review of the Safety of Interleukin-17A Inhibitor Secukinumab
Vishnu Eshwar, Ashwin Kamath, Rajeshwari Shastry, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 11, pp. 1365-1365
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Diversification of Phage-Displayed Peptide Libraries with Noncanonical Amino Acid Mutagenesis and Chemical Modification
J. Trae Hampton, Wenshe R. Liu
Chemical Reviews (2024) Vol. 124, Iss. 9, pp. 6051-6077
Open Access | Times Cited: 18
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
Susanne Klint, Joachim Feldwisch, Lindvi Gudmundsdotter, et al.
mAbs (2023) Vol. 15, Iss. 1
Open Access | Times Cited: 33
Assessment of safety profile of secukinumab in real-world scenario using United States food and drug administration adverse event reporting system database
Vishnu Eshwar, Ashwin Kamath
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
The role of interleukin-17 in inflammation-related cancers
Xingru Zhang, Bin Li, Lü Tian, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function
Anella Saviano, Adel Abo Manosour, Federica Raucci, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 11, pp. 1415-1428
Open Access | Times Cited: 13
The preclinical discovery and development of secukinumab for the treatment of moderate-to-severe hidradenitis suppurativa
Klaudia Knecht-Gurwin, Łukasz Matusiak, Jacek C. Szepietowski
Expert Opinion on Drug Discovery (2025)
Closed Access
Clinical features, treatment, and prognosis of secukinumab-induced inflammatory bowel disease
Ronghui Li, Haibo Lei, Chunjiang Wang, et al.
European journal of medical research (2025) Vol. 30, Iss. 1
Open Access
At The Interface: Small-Molecule Inhibitors of Soluble Cytokines
Raavi, Angela N. Koehler, Arturo J. Vegas
Chemical Reviews (2025)
Closed Access
Secukinumab for the Treatment of Psoriasis in Pediatrics: Patient Selection and Acceptability
Joanna Narbutt, Michał Niedźwiedź, Aleksandra Lesiak, et al.
Patient Preference and Adherence (2023) Vol. Volume 17, pp. 421-431
Open Access | Times Cited: 10
Emerging Medical Therapies in Rosacea: A Narrative Review
James Choe, John S. Barbieri
Dermatology and Therapy (2023) Vol. 13, Iss. 12, pp. 2933-2949
Open Access | Times Cited: 8
Clinical advances in biological therapy for generalized pustular psoriasis: a review
Chang‐Yu Hsieh, Tsen‐Fang Tsai
Expert Opinion on Biological Therapy (2024) Vol. 24, Iss. 1-2, pp. 37-50
Closed Access | Times Cited: 2
Effects of secukinumab and ixekizumab on major adverse cardiovascular events in patients with psoriasis: a meta-analysis of randomized controlled trials
Yonghong Zhang, Zhiya Yang, Jinyan Gong, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 2
The Impact of Psoriasis Treatments on the Risk of Skin Cancer: A Narrative Review
Luca Potestio, Nello Tommasino, Giuseppe Lauletta, et al.
Advances in Therapy (2024) Vol. 41, Iss. 10, pp. 3778-3791
Closed Access | Times Cited: 2
Unleashing the Power of IL-17: A Promising Frontier in Chronic Obstructive Pulmonary Disease (COPD) Treatment
Christine Henen, Elise A Johnson, Shimshon Wiesel
Cureus (2023)
Open Access | Times Cited: 5
Anti-IL17 treatment in childhood chronic rheumatic diseases
Valerio Maniscalco, Ilaria Maccora, Flavio Girodo, et al.
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 5, pp. 429-441
Closed Access | Times Cited: 4
Innate Immune Response and Epigenetic Regulation: A Closely Intertwined Tale in Inflammation
Diksha Jawale, Shweta Khandibharad, Shailza Singh
Advanced Biology (2024)
Closed Access | Times Cited: 1
Pharmacotherapeutic management of psoriatic disease: addressing psoriatic Arthritis and cutaneous manifestations
Robin C. Yi, Hannah Y. Gantz, Shimul A. Shah, et al.
Expert Opinion on Pharmacotherapy (2024) Vol. 25, Iss. 16, pp. 2203-2212
Closed Access | Times Cited: 1
Darier disease: Current insights and challenges in pathogenesis and management
Monika Ettinger, Susanne Kimeswenger, I. Deli, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 1
Incremental Cardiovascular Risk of Menopause in Women with Psoriasis, Psoriatic Arthritis or Spondyloarthritis?
Donna E. Vegt, D A Popa-Diaconu, Michelle L M Mulder, et al.
Current Rheumatology Reports (2024) Vol. 27, Iss. 1
Closed Access | Times Cited: 1
Control of porphyria cutanea tarda with anti-IL-17 secukinumab in a person with psoriasis living with HIV
Helbies Bedier, Stéphane Isnard, Réjean Thomas, et al.
Oxford Medical Case Reports (2023) Vol. 2023, Iss. 7
Open Access | Times Cited: 2
Incidence of New-Onset Inflammatory Bowel Disease, Oral and Gastrointestinal Candidiasis, Herpes Zoster, Pulmonary Tuberculosis, and Major Cardiovascular Events in Patients with Moderate-to-Severe Psoriasis Exposed to Biologics
Da‐Hyun Kang, Bark‐Lynn Lew, Soon‐Hyo Kwon
Journal of Clinical Medicine (2023) Vol. 12, Iss. 24, pp. 7653-7653
Open Access | Times Cited: 2
Biologics protect psoriasis patients from being exacerbated by COVID-19 infection
Yuxin Zheng, Xi‐Bei Chen, Zhaoyuan Wang, et al.
Heliyon (2024) Vol. 10, Iss. 2, pp. e24534-e24534
Open Access
A case of concomitant juvenile idiopathic arthritis (JIA) and paediatric-onset multiple sclerosis (POMS) – treatment with secukinumab and dimethyl fumarate followed by ofatumumab
Aleksandra Jartych, Anna Jamróz-Wiśniewska, Konrad Rejdak, et al.
Journal of Pre-Clinical and Clinical Research (2024) Vol. 1, Iss. 18, pp. 16-20
Open Access
Vasculitis associated with psoriatic arthritis: a case report
Mehdi Jafarpour, Bita Rahbari, Bahareh Mehramuz, et al.
Egyptian Rheumatology and Rehabilitation (2024) Vol. 51, Iss. 1
Open Access
Molecular Insights into the Therapeutic Mechanisms of BuShen-QiangDu-ZhiLv Decoction for Ankylosing Spondylitis
Mengyang Ma, Zhihua Yang, Ke Li, et al.
Journal of Ethnopharmacology (2024) Vol. 340, pp. 119269-119269
Closed Access
Page 1 - Next Page

Scroll to top